History repeats itself: Pharmacodynamic trends in the treatment of anxiety disorders

Current Pharmaceutical Design

Volumn 11, Issue 2, 2005, Pages 255-263

  Schwartz, T L ^a   Nihalani, N ^a   Simionescu, M ^a   Hopkins, G ^a  

^a State University of New York Upstate Medical University: College of Medicine   (United States)

Author keywords

Anxiety; GABA; Medication; Seretonin

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR; ALCOHOL; ALPRAZOLAM; BARBITURIC ACID DERIVATIVE; BENZODIAZEPINE DERIVATIVE; BROMAZEPAM; CHLORAL HYDRATE; CITALOPRAM; CLOBAZAM; CLOMIPRAMINE; CLONAZEPAM; CLORAZEPATE; DIAZEPAM; FLUOXETINE; FLUVOXAMINE; GABAPENTIN; LORAZEPAM; MEPROBAMATE; MOCLOBEMIDE; PAROXETINE; POTASSIUM BROMIDE; PRAZEPAM; PROPRANOLOL; SECBUTABARBITAL; SEROTONIN AGONIST; SERTRALINE; TETRABAMATE; TRIAZOLAM; UNINDEXED DRUG; VALPROIC ACID;

ANXIETY DISORDER; ANXIETY NEUROSIS; ATAXIA; BEHAVIOR DISORDER; CLINICAL TRIAL; DEPRESSION; DOSE RESPONSE; DRUG ABSORPTION; DRUG ALCOHOL INTERACTION; DRUG APPROVAL; DRUG HALF LIFE; DRUG MARKETING; DRUG MECHANISM; DRUG METABOLISM; DRUG OVERDOSE; EPILEPSY; HUMAN; PANIC; PHARMACODYNAMICS; PRIORITY JOURNAL; REVIEW; SOMNOLENCE; WITHDRAWAL SYNDROME;

ANTI-ANXIETY AGENTS; ANXIETY DISORDERS; DOUBLE-BLIND METHOD; GABA MODULATORS; HISTORY, 20TH CENTURY; HUMANS; PHARMACOLOGY; RANDOMIZED CONTROLLED TRIALS; SEROTONIN UPTAKE INHIBITORS;

EID: 11844283296     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/1381612053382214     Document Type: Review

References (100)

1. Estes JW. The road to tranquility: the search for selective anti-anxiety agents. Synapse 1995; 21(1): 10-20.
2. Kushner MG, Mackenzie, Thomas B, Fiszdon J, Valentiner DP, Foa E, et al. The effects of alcohol consumption on laboratory-induced panic and state anxiety. Archives of General Psychiatry 1996; 53(3): 264-70.
3. Kushner MG, Sher KJ, Beitman BD. The relation between alcohol problems and the anxiety disorders. Am J Psychiatry 1990; 147: 685-95.
4. Khantzian EJ. The alcoholic patient: an overview. Am J Psychotherapy 1980; 34(1): 685-95
5. Eddy CC. The effects of alcohol on anxiety in problem- and nonproblem- drinking women. Clin Exper Res 1979; 3(2): 107-114.
6. Holroyd KA. Effects of social anxiety and social evaluation on beer consumption and social interaction. J Studies of Alcohol 1978; 39(5): 737-44.
7. Stahl SM. Essential psychopharmacology: Neuroscientific basis and practical applications. 2cd edn. Cambridge University Press: New York, 2000.
8. Uhlenhuth EH, Canter A, Neustadt JO, Payson HE. The symptomatic relief of anxiety with meprobamate, phenobarbital and placebo. Am J Psychiatry 1959; 115(10): 905-10.
9. Uhlenhuth EH, Covi L, Rickels K, Lipman RS, Park LC. Predicting the relief of anxiety with meprobamate: An attempt at replication. Arch Gen Psychiatry 1972; 26(1): 85-91.
10. Zawertailo LA, Busto UE, Kaplan HL, Greenblatt DJ, Sellers EM. Comparative abuse liability and pharmacological effects of meprobamate, triazolam, and butabarbital. J Clin Psychopharmacol 2003; 23(3): 269-80.
11. Roache JD, Griffiths RR. Lorazepam and meprobamate dose effects in humans: behavioral effects and abuse liability. J Pharmacol Exp Ther 1987; 243(3): 978-88.
12. Loo H, Malka R, Hantouche E, Lancrenon S, Guelfi JD. A controlled double-blind study of tetrabamate versus lorazepam and placebo in generalized anxiety. Encephale 1991; 17(4): 295-300.
13. Sonne LM, Holm P. A comparison between bromazepam (Ro 5-3350, Lexotan) and diazepam (Valium) in anxiety neurosis: A controlled, double-blind clinical trial. International Pharmacopsychiatry 1975; 10(2): 125-28.
14. Whitehead WE, Blackwell B, Robinson A. Effects of diazepam on phobic avoidance behavior and phobic anxiety. Biological Psychiatry 1978; 13(1): 59-64.
15. Dasberg H. Oral diazepam in hospitaized anxiety patients (with observations on concentration-effect-relationships). Pharmakopsychiatrie Neuro-Psychopharmakologie 1975; 8(4): 162-69.
16. Kellner R, Wilson RM, Muldawer MD, Pathak D. Anxiety in schizophrenia: The responses to chlordiazepoxide in an intensive design study. Arch Gen Psychiatry 1975; 32(10): 1246-54.
17. Burrows GD, Dumovic P, Smith JA, Norman T, Maguire K. A controlled comparative trial of clorazepate (Tranxene) and diazepam (Valium) for anxiety. Medical Journal of Australia 1977; 2(16): 525-28.
18. Aden GC, Thein SG Jr. Alprazolam compared to diazepam and placebo in the treatment of anxiety. Journal of Clinical Psychiatry 1980; 41(7): 245-48.
19. Rickels K, Brown AS, Cohen D, Harris H, Hurowitz A, Lindenbaum EJ, et al. Clobazam and diazepam in anxiety. Clinical Pharmacology & Therapeutics 1981; 30(1): 95-100.
20. Jacobson AF, Goldstein BJ, Dominguez RA, Steinbook RM. A placebo-controlled, double-blind comparison of clobazam and diazepam in the treatment of anxiety. Journal of Clinical Psychiatry 1983; 44(8): 296-300.
21. Dorman T. A multi-centre comparison of prazepam and diazepam in the treatment of anxiety. Pharmatherapeutica 1983; 3(6): 433-40.
22. Noyes R Jr, Anderson DJ, Clancy J, Crowe RR, Slymen DJ, Ghoneim MM, Hinrichs JV. Diazepam and propranolol in panic disorder and agoraphobia. Archives of General Psychiatry 1984; 41(3): 287-92.
23. Dunner DL, Ishiki D, Avery DH, Wilson LG, Hyde TS. Effect of alprazolam and diazepam on anxiety and panic attacks in panic disorder: a controlled study. Journal of Clinical Psychiatry 1986; 47(9): 458-60.
24. Tesar GE, Rosenbaum JF, Pollack MH, Otto MW, Sachs GS, Herman JB, et al. Double-blind, placebo-controlled comparison of clonazepam and alprazolam for panic disorder. J Clin Psychiatry 1991; 52(2): 69-76.
25. Pols H, Zandbergen J, Lousberg H, de Loof C, Griez E. Low doses of clonazepam, in the treatment of panic disorder. Can J Psychiatry 1991; 36(4): 302-3.
26. Rosenbaum JF, Moroz G, Bowden CL. Clonazepam in the treatment of panic disorder with or without agoraphobia: a dose-response study of efficacy, safety, and discontinuance. Clonazepam Panic Disorder Dose-Response Study Group. J Clin Psychopharmacol 1997; 17(5): 390-400.
27. Valenca AM, Nardi AE, Nascimento I, Mezzasalma MA, Lopes FL, Zin W. Double-blind clonazepam vs placebo in panic disorder treatment. Arq Neuropsiquiatr 2000; 58(4): 1025-29.
28. Worthington JJ 3rd, Pollack MH, Otto MW, McLean RY, Moroz G, Rosenbaum JF. Long-term experience with clonazepam in patients with a primary diagnosis of panic disorder. Psychopharmacol Bull 1998; 34(2): 199-205.
29. Pollack MH, Otto MW, Tesar GE, Cohen LS, Meltzer-Brody S, Rosenbaum JF. Long-term outcome after acute treatment with alprazolam or clonazepam for panic disorder. J Clin Psychopharmacol 1993; 13(4): 257-63.
30. Ontiveros A, Fontaine R. Sodium valproate and clonazepam for treatment-resistant panic disorder. J Psychiatry Neurosci 1992; 17(2): 78-80.
31. Pollack MH, Simon NM, Worthington JJ, Doyle AL, Peters P. Toshkov F, et al. Combined paroxetine and clonazepam treatment strategies compared to paroxetine monotherapy for panic disorder. J Psychopharmacol 2003; 17(3): 276-82.
32. Goddard AW, Brouette T, Almai A, Jetty P, Woods SW, Charney D. Early coadministration of clonazepam with sertraline for panic disorder. Arch Gen Psychiatry 2001; 58(7): 681-86.
33. Moroz G, Rosenbaum JF. Efficacy, safety, and gradual discontinuation of clonazepam in panic disorder: a placebo-controlled, multicenter study using optimized dosages. J Clin Psychiatry 1999; 60(9): 604-12.
34. Fontaine R, Annable L, Chouinard G, Ogilvie RI. Bromazepam and diazepam in generalized anxiety: a placebo-controlled study with measurement of drug plasma concentrations. Journal of Clinical Psychopharmacology 1983; 3(2): 80-7.
35. Spenard J, Caille G, de Montigny C, Vezina M, Ouellette J, Lariviere L, et al. Placebo-controlled comparative study of the anxiolytic activity and of the pharmacokinetics of oral and sublingual lorazepam in generalized anxiety. Biopharm Drug Dispos 1988; 9(5): 457-64.
36. Elie R, Lamontagne Y. Alprazolam and diazepam in the treatment of generalized anxiety. J Clin Psychopharmacol 1984; 4(3): 125-9.
37. Saddock BJ, Saddock VA. Kaplan & saddock's pocket handbook of psychiatric drug treatment. 3rd edn. Lippincott, Williams, & Wilkins: USA, 2001.
38. Zohar J, Westenberg HG. Anxiety disorders: a review of tricyclic antidepressants and selective serotonin reuptake inhibitors. Acta Psychiatr Scand 2000; 403: 39-49.
39. Vaswani M, Linda FK, Ramesh S. Role of selective serotonin reuptake inhibitors in psychiatric disorders : a comprehensive review. Progress in Neuro-Psychopharmacology and Biological Psychiatry 2003; 27(1): 85-102.
40. Versiani M. A review of 19 double-blind placebo-controlled studies in social anxiety disorder (social phobia). World Journal of Biological Psychiatry 2000; 1(1): 27-33.
41. Marshall RD, Schneier FR, Fallon BA, Knight CB, Abbate LA, Goetz D, et al. An open trial of paroxetine in patients with noncombat-related, chronic posttraumatic stress disorder. J. Clin. Psychopharmacol 1998; 18(1): 10-18.
42. Rapaport MH, Wolkow R, Rubin A, Hackett E, Pollack M, Ota KY. Sertraline treatment of panic disorder: results of a long-term study. Acta Psychiatr Scand 2001; 104(4): 289-98.
43. Cook EH, Wagner KD, March JS, Biederman J, Landau P, Wolkow R, et al. Long-term sertraline treatment of children and adolescents with obsessive-compulsive disorder. J Am Acad Child Adolesc Psychiatry 2001; 40(10): 1175-81.
44. Londborg PD, Wolkow R, Smith WT. DuBoff E, England D, Ferguson J, et al. Sertraline in the treatment of panic disorder. A multi-site, double-blind, placebo-controlled, fixed-dose investigation. Br J Psychiatry 1998; 173: 54-60.
45. Kelsey JE, Nemeroff CB. Selective serotonin reuptake inhibitors. In: Sadock BJ, Sadock VA. (eds). Comprehensive Textbook of Psychiatry 2: Lippincott Williams and Wilkins, USA, 2000; pp 2432-44.
46. Boyer W. Serotonin uptake inhibitors are superior to imipramine and alprazolam in alleviating panic attacks: a meta-analysis. Int Clin Psychopharmacol 1995; 10(1): 45-49.
47. Figgitt DP, McClellan KJ. Fluvoxamine. An updated review of its use in the management of adults with anxiety disorders. Drugs 2000; 60(4):925-54.
48. Van der Kolk BA, Dreyfuss D, Michaels M, Shera D, Berkowitz R, Fisler R, et al. Fluoxetine in posttraumatic stress disorder. J Clin Psychiatry 1994; 55(12): 517-22.
49. Davidson JR, Malik ML, Sutherland SN. Response characteristics to antidepressants and placebo in post-traumatic stress disorder. Int Clin Psychopharmacol 1997; 12(6): 291-6.
50. Koponen H, Lepola U, Leinonen E, Jokinen R, Penttinen J, Turtonen J. Citalopram in the treatment of obsessive compulsive disorder: an open pilot study. Acta Psychiatr Scand 1997; 96: 343-6.
51. De Boer M, Op den Velde W, Falger PJ, Hovens JE, De Groen JH, Van Duijn H. Fluvoxamine treatment for chronic PTSD: a pilot study. Psychother Psychosom 1992; 57(4): 158-63.
52. Rickels K, Schweizer E. The treatment of generalized anxiety disorder in patients with depressive symptornatology. J Clin Psychiatry 1993; 54 Suppl: 20-3.
53. Noyes R Jr, Garvey MJ, Cook BL. Follow-up study of patients with panic disorder and agoraphobia with panic attacks treated with tricyclic antidepressants. J Affect Disord 1989; 16(2-3): 249-57.
54. Trimble MR. Worldwide use of clomipramine. J Clin Psychiatry 1990; 51 Suppl: 51-54; discussion 55-8.
55. Falcon S, Ryan C, Chamberlain K, Curtis G. Tricyclics: possible treatment for posttraumatic stress disorder. J Clin Psychiatry 1985; 46(9): 385-8.
56. Bonnet U. Moclobemide: therapeutic use and clinical studies. CNS Drug Reviews 2003 Spring; 9(1): 97-140.
57. Blanco C, Antia SX, Liebowitz MR. Pharmacotherapy of social anxiety disorder. [Review] Biological Psychiatry 2002; 51(1): 109-20.
58. Liebowitz MR, Hollander E, Schneier F, Campeas R, Welkowitz L, Hatterer J, et al. Reversible and irreversible monoamine oxidase inhibitors in other psychiatric disorders. Acta Psychiatrica Scandinavica Suppl 1990; 360: 29-34.
59. Harvey AT, Rudolph RL, Preskorn SH. Evidence of the dual mechanisms of action of venlafaxine. Archives of General Psychiatry 2000; 57: 503-9.
60. Moyer JA, Muth EA, Haskins JT, Lappe RW, Sigg EB. In vivo antidepressant profiles of the novel bicyclic compounds Wy-45,030 and Wy-45,881 [abstract]. Soc Neurosci Abstracts 1984; 10: 261.
61. Beique JC, de Montigny C, Blier P, Debonnel G. Blockade of 5-hydroxytryptamine and noradrenaline uptake by venlafaxine: a comparative study with paroxetine and desipramine, Brit J Pharmacol 1998; 125(3): 526-32.
62. Davidson JR, DuPont RL, Hedges D, Haskins JT. Efficacy, safety, and tolerability of venlafaxine extended release and buspironein outpatients with generalized anxiety disorder. J Clin Psychiat 1999; 60(8): 528-35.
63. Allgulander C, Hackett D, Salinas E. Venlafaxine extended release (ER) in the treatment of generalised anxiety disorder: twenty-four-week placebo-controlled dose-ranging study. Br J Psychiatry 2001; 179:15-22.
64. Gorman JM. Treating generalized anxiety disorder. Journal of Clinical Psychiatry 2003; 64(2): 24-9.
65. Gelenberg AJ, Lydiard RB, Rudolph RL, et al. Efficacy of venlafaxine extended-release capsules in nondepressed outpatients with generalized anxiety disorder: A 6-month randomized controlled trial. JAMA 2000; 283: 3082-8.
66. Meoni P, Hackett D. Characterization of the longitudinal course of long-term venlafaxine XR treatment of GAD. Int J Neuropsychopharmacol 2000; 3: S282
67. Rickels K, Weisman K, Norstad N, Singer M, Stoltz D, Brown A, et al. Buspirone and diazepam in anxiety: a controlled study. J Clin Psychiatry 1982; 43: 81-6.
68. Goldberg HL, Finnerty RJ. The comparative efficacy of buspirone and diazepam in the treatment of anxiety. Am J Psychiatry 1979; 136:1184-7.
69. Pohl R, Balon R, Yeragani VK, Gershon S. Serotonergic anxiolytics in the treatment of panic disorder: a controlled study with buspirone. Psychopathology 1989; 22(1): 60-7.
70. Sheehan DV, Raj AB, Hamett-Sheehan K, Soto S, Knapp E. The relative efficacy of high-dose buspirone and alprazolam in the treatment of panic disorder: a double-blind placebo-controlled study. Acta Psychiatr Scand 1993; 88: 1-11.
71. Pecknold JC. Serotonin 5-HT1A agonists: a comprehensive review. CNS Drugs 1994; 2: 234-51.
72. Tunnieliff G. Molecular basis of buspirone's anxiolytic action. Pharmacol Toxicol 1991; 69: 149-56.
73. Rickels K, Schweizer E, DeMartinis N, Mandos L, Mercer C. Gepirone and diazepam in generalized anxiety disorder: a placebo-controlled trial. Journal of Clinical Psychopharmacology 1997; 17(4): 272-7.
74. Cutler NR, Sramek JJ, Keppel Hesselink JM, Krol A, Roeschen J, Rickels K, et al. A double-blind, placebo-controlled study comparing the efficacy and safety of ipsapirone versus lorazepam in patients with generalized anxiety disorder: a prospective multicenter trial. J Clin Psychopharmacol 1993; 13(6): 429-37.
75. Mandos LA, Rickels K, Cutler N, Roeschen J, Keppel Hesselink JM, Schweizer E. Placebo-controlled comparison of the clinical effects of rapid discontinuation of ipsapirone and lorazepam after 8 weeks of treatment for generalized anxiety disorder. Int Clin Psychopharmacol 1995; 10(4): 251-6.
76. Laakmann G, Schule C, Lorkowski G, Baghai T, Kuhn K, Ehrentraut S. Buspirone and lorazepam in the treatment of generalized anxiety disorder in outpatients. Psychopharmacology (Berl) 1998; 136(4): 357-66.
77. Ross CA, Matas M. A clinical trial of buspirone and diazepam in the treatment of generalized anxiety disorder. Canadian Journal of Psychiatry - Revue Canadienne de Psychiatric 1987; 32(5): 351-5.
78. Taylor CP, Gee NS, Su TZ, Kocsis JD, Welty DF, Brown JP, et al. A summary of mechanistic hypotheses of gabapentin pharmacology. Epilepsy Res 1998; 29(3): 233-49.
79. Pande AC, Davidson JR, Jefferson JW, et al. Treatment of social phobia with gabapentin: a placebo-controlled study. J Clin Psychopharmacol 1999; 19: 341-8.
80. Hamner MB, Brodrick PS, Labbate LA. Gabapentin in PTSD: a retrospective, clinical series of adjunctive therapy. Ann Clin Psychiat 200 1; 13(3): 141-6.
81. Pande AC, Pollack MH, Crockatt J, Greiner M, Chouinard G, Lydiard RB, et al. Placebo-controlled study of gabapentin treatment of panic disorder. J Clin Psychopharmacol 2000; 20(4): 467-71.
82. Megna JL, Iqbal MM, Aneja A. Pharmacology and Therapeutics of gabapentin in the treatment of psychiatric disorders; present and future perspectives. Current Neuropharmacology 2003; 1: 187-97.
83. Borden LA, Murali Dhar TG, Smith KE, Weinshank RL, Branchek TA, Gluchowski C. Tiagabine, SK & F 89976-A, CI-966, and NNC-711 are selective for the coined GABA transporter GAT-1. Eur J Pharmacol 1994; 269: 219-24.
84. Mathias S, Wetter TC, Steiger A, Lance M. The GABA uptake inhibitor tiagabine promotes slow wave sleep in normal elderly subjects. Neurobiol Aging 2001; 22: 247-53.
85. Schwartz TL. The use of tiagabine augmentation for treatment resistant anxiety disorders: a case series. Psychopharmacol Bull 2002; 36: 53-7.
86. Gruener DM, Finkelstein S. Tiagabine for the treatment of anxiety and comorbid pain. Poster presented at: American Psychiatric Association Annual Meeting 2003; San Francisco, CA. NR poster 734.
87. Berigan T. Treatment of posttraumatic stress disorder with tiagabine. Can J Psychiatry 2002; 47: 788.
88. Crane DL. Tiagabine for the treatment of anxiety. Depress Anxiety 2003; In press.
89. Rosenthal M. Tiagabine for the treatment of generalized anxiety disorder: A randomized, open-label, clinical trial with paroxetine as a positive control. J Clin Psychiatry 2003; in press.
90. Connor K, Weisler R, Zhang W, Abraham K, Darwish M, Davidson J. Tiagabine for posttraumatic stress disorder. Poster presented at: American Psychiatric Association Annual Meeting; May 17-22, 2003; San Francisco, CA. NR poster 823.
91. Schwartz TL, Nouman A, Husain J, et al. Tiagabine as augmentation therapy for anxiety disorders. Poster presented at: American Psychiatric Association Annual Meeting; 2003; San Francisco, CA. NR poster 157.
92. Fink K, Dooley DJ, Meder WP, Suman-Chauhan N, Duffy S, Clusmann H, et al. Inhibition of neuronal Ca(2+) influx by gabapentin and pregabalin in the human neocortex. Neuropharmacology 2002; 42(2): 229-36.
93. Pande AC, Crockatt JG, Feltner DE, Janney CA, Smith WT, Weisler R, et al. Pregabalin in generalized anxiety disorder: a placebo-controlled trial. Am J Psychiat 2003; 160(3): 533-40.
94. Feltner DE, Crockatt JG, Dubovsky SJ, Cohn CK, Shrivastava RK, Targum SD, et al. A randomized, double-blind, placebo-controlled, fixed dose, multicenter study of pregabalin in patients with generalized anxiety disorder. J Clin Psychopharmacol 2003; 23(3): 240-9.
95. Guilinello M, Smith SS. Anxiogenic effects of neurosteroid exposure: Sex differences andalterede GABA-A receptor pharmacology in adult rats. J of Pharm and Exp Ther Fast Forward 2003; 305(2): 541-48.
96. Navarro JF, Buron E, Martin-Lopez M. Anxiogenic-like activity of L-655,708, a selective ligand for the benzodiazepine site of GABA(A) receptors which contain the alpha-5 subunit, in elevated plus-maze effect. Progress in Neuro-Psychopharmacology & Biological Psychiatry 2002; 26(7-8): 1389-92.
97. Hodge CW, Rabor J, McMahon T, Walter H, Sanchez-Perez AM, Olive MF, et al. Decreased anxiety-like behavior, reuced stress hormones, and neurosteroid supersensitivity in mice lacking protein kinase C[varepsion]. Journal of Clinical Investigation 2002; 110(7): 1003-1010.
98. Bateson AN. Basic pharmacologic mechanisms involved in benzodiazepine tolerance and withdrawal. Curr Pharm Design 2002; 8(1): 5-21.
99. Schechter LE, Dawson LA, Harder JA. The potential utility of 5-HT1A receptor antagonists in the treatment of cognitive dysfunction associated with Alzheimer s disease. Curr Pharm Design 2002; 8(2): 139-45.
100. Westra HA, Stewart SH. As-needed use of benzodiazepines in managing clinical anxiety: incidence and implications. Curr Pharm Design 2002; 8(1): 59-74.